The magnitude of therapeutic success correlates with type of venom, duration of therapy, and venom dose. Adult-onset MIS and/or a BTC > 20 μg/L is a significant, albeit not the strongest determinant for VIT failure. According to its odds ratio, ACE inhibitor therapy appears to be associated with the highest risk for VIT failure.

No abstract

A565 patients in the UK. Methods: Moderate to severe PsO patients in the UK Hospital Treatment Insights (HTI) database with 1-year wash-out prior to first dispense, who completed induction and were on continued maintenance treatment during 1-year follow-up were included. We used two consecutive maintenance average daily doses ≥ 30% or ≥ 10% higher than indicated in the UK Summary of Product Characteristics (SPC) to assess above-label dose and estimated percentage of patients on above-label dose, mean time on above-label dose and extra costs per patient associated with above-label use relative to on-label use of biologics over the 1-year of follow-up period. Results: The final eligible sample included 362 PsO patients (adalimumab (

No abstract